China is the first country to approve AstraZeneca’s drug for anaemia patients with kidney disease
Roxadustat approved in China for the treatment of anaemia in non-dialysis-dependent patients with chronic kidney disease China is the first country to approve roxadustat for all chronic kidney disease patients with anaemia AstraZeneca today announced that its partner FibroGen (China) Medical Technology Development Co., Ltd. (FibroGen China) has received marketing authorisation for roxadustat in China…
